Table 3.
Summary of All-Grade Adverse Events.
| TACE + lenvatinib + PD-1 inhibitors (n = 23) | TACE + lenvatinib (n = 32) | TACE + sorafenib (n = 29) | P-value | |
|---|---|---|---|---|
| All-grade | 18 (78.26) | 24 (75) | 24 (82.75) | .761 |
| Fever | 18 (78.26) | 23 (71.88) | 22 (75.86) | .857 |
| Elevated ALT | 17 (73.91) | 20 (62.5) | 22 (75.86) | .471 |
| Elevated AST | 16 (69.57) | 21 (65.63) | 21 (72.41) | .847 |
| Abdominal pain | 11 (47.82) | 13 (40.63) | 15 (51.72) | .678 |
| Nausea | 5 (21.74) | 3 (9.38) | 1 (3.45) | .101 |
| Hypertension | 5 (21.74) | 8 (25.00) | 2 (6.90) | .155 |
| Loss of appetite | 3 (13.04) | 3 (9.38) | 4 (13.79) | .851 |
| Diarrhea | 3 (13.04) | 2 (20.00) | 5 (17.24) | .408 |
| Fatigue | 3 (13.04) | 3 (9.38) | 3 (10.34) | .907 |
| Rash | 3 (13.04) | 3 (9.38) | 6 (20.69) | .443 |
| Hypothyroidism | 2 (8.70) | 1 (3.13) | 0 | .241 |
| Hand-foot syndrome | 1 (4.35) | 2 (0.00) | 15 (51.72) | 0 |
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; RECIST, modified response evaluation criteria in solid tumors; PD-1, programmed death 1; TACE, transarterial chemoembolization.